BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Breast Cancer: HER2+ Disease Coverage

May 09, 2018

The approval of Herceptin (trastuzumab) in 1998 transformed the treatment of this aggressive disease, leading to increased disease-free progression and survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The subsequent development of additional HER2-targeted therapies has increased the treatment options available to patients, although Herceptin continues to dominate in the majority of treatment settings. HER2 is overexpressed in approximately 25% of breast cancers, and is associated with more aggressive tumors, poor short-term survival rates, and poor overall outcomes.

This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.

Disease Group Covered: Oncology
Back to the top Back to the top